By Gina Shaw
BOSTON—Early empirical double coverage with an aminoglycoside added to cefepime for the initial management of febrile neutropenia offers no significant difference in outcomes compared with monotherapy, according to a new study presented at the 2022 annual meeting of the Hematology/Oncology Pharmacy Association.
APRIL 1, 2022